These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 28462837)

  • 1. Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ET
    Khadtare N; Stephani R; Korlipara V
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2281-2285. PubMed ID: 28462837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acids as selective ET(A) antagonists.
    Patel HJ; Olgun N; Lengyel I; Reznik S; Stephani RA
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6840-4. PubMed ID: 20932745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and bioactivity of pyrazole acid derivatives as endothelin receptor antagonists.
    Cai J; Liu L; Chen J; Cao M; Ji M
    Med Chem; 2013 Dec; 9(8):1113-22. PubMed ID: 23521004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonaryl, highly selective ETA antagonist (A-216546).
    Liu G; Henry KJ; Szczepankiewicz BG; Winn M; Kozmina NS; Boyd SA; Wasicak J; von Geldern TW; Wu-Wong JR; Chiou WJ; Dixon DB; Nguyen B; Marsh KC; Opgenorth TJ
    J Med Chem; 1998 Aug; 41(17):3261-75. PubMed ID: 9703472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of 3-quinoline carboxylic acids as new inhibitors of protein kinase CK2.
    Syniugin AR; Ostrynska OV; Chekanov MO; Volynets GP; Starosyla SA; Bdzhola VG; Yarmoluk SM
    J Enzyme Inhib Med Chem; 2016; 31(sup4):160-169. PubMed ID: 27590574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of phenoxybutanoic acid derivatives as potent endothelin antagonists with antihypertensive activity.
    Cai J; Liu L; Hong KH; Wang P; Li L; Cao M; Sun C; Wu X; Zong X; Chen J; Ji M
    Bioorg Med Chem; 2015 Feb; 23(4):657-67. PubMed ID: 25614116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.
    Yoshizumi T; Takahashi H; Ohtake N; Jona H; Sato Y; Kishino H; Sakamoto T; Ozaki S; Takahashi H; Shibata Y; Ishii Y; Saito M; Okada M; Hayama T; Nishikibe M
    Bioorg Med Chem; 2004 May; 12(9):2139-50. PubMed ID: 15080914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and endothelin receptor binding affinity of a novel class of 2-substituted-4-aryl-3-quinolinecarboxylic acid derivatives.
    Pittalà V; Modica M; Salerno L; Siracusa MA; Guerrera F; Mereghetti I; Cagnotto A; Mennini T; Romeo G
    Med Chem; 2008 Mar; 4(2):129-37. PubMed ID: 18336332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of 2-substituted D-tryptophan-containing peptidic endothelin receptor antagonists: importance of the C-2 substituent of the D-tryptophan residue for endothelin A and B receptor subtype selectivity.
    Fukami T; Yamakawa T; Niiyama K; Kojima H; Amano Y; Kanda F; Ozaki S; Fukuroda T; Ihara M; Yano M; Ishikawa K
    J Med Chem; 1996 Jun; 39(12):2313-30. PubMed ID: 8691426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
    Aubert JD; Juillerat-Jeanneret L
    J Med Chem; 2016 Sep; 59(18):8168-88. PubMed ID: 27266371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ETA/ETB mixed antagonists.
    Jae HS; Winn M; Dixon DB; Marsh KC; Nguyen B; Opgenorth TJ; von Geldern TW
    J Med Chem; 1997 Sep; 40(20):3217-27. PubMed ID: 9379441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-(2-(4-substitutedpiperazin-1-yl)acetyl)piperazin-1-yl)quinoline-3-carboxylic acid derivatives as anti-tubercular and antibacterial agents.
    Suresh N; Nagesh HN; Renuka J; Rajput V; Sharma R; Khan IA; Kondapalli Venkata Gowri CS
    Eur J Med Chem; 2014 Jan; 71():324-32. PubMed ID: 24333580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA; Soeding PF; Hughes RJA; Wright CE
    Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics.
    Dupuis J
    Can J Cardiol; 2000 Jul; 16(7):903-10. PubMed ID: 10934309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, structure, and antibacterial activity of 4-imino-1, 4-dihydrocinnoline-3-carboxylic acid and 4-oxo-1, 4-dihydrocinnoline-3-carboxylic acid derivatives as isosteric analogues of quinolones.
    Stańczak A; Ochocki Z; Martynowski D; Główka M; Nawrot E
    Arch Pharm (Weinheim); 2003 Mar; 336(1):18-30. PubMed ID: 12666250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and endothelin receptors binding affinity of new 1,3,5- substituted pyrrole-2-carboxylic acid derivatives.
    Salerno L; Modica MN; Romeo G; Pittala V; Cagnotto A; Siracusa MA
    Med Chem; 2015; 11(2):109-17. PubMed ID: 25229828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors.
    Sechi M; Rizzi G; Bacchi A; Carcelli M; Rogolino D; Pala N; Sanchez TW; Taheri L; Dayam R; Neamati N
    Bioorg Med Chem; 2009 Apr; 17(7):2925-35. PubMed ID: 19026554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships of a novel series of orally active nonpeptide ETA and ETA/B endothelin receptor-selective antagonists.
    Doherty AM; Patt WC; Repine J; Edmunds JJ; Berryman KA; Reisdorph BR; Walker DM; Haleen SJ; Keiser JA; Flynn MA
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S358-61. PubMed ID: 8587414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
    Rafnsson A; Shemyakin A; Pernow J
    Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.